Galactosamine liver necrosis

Fig. 6. The role of endogenous tumor necrosis factor TNF) in D-galactosamine (GalN)-induced liver damage. All mice were injected with 2.1 g/kg GalN. Serum transaminases ALT) and hepatic DNA fragmentation were determined after 24 h. Animals pretreated with neutralizing anti-TNF antibodies or mice lacking TNF receptor-1 tnf-rl°) were protected...

Much of the pharmacology of FPL-55712 is ascribed to its antagonism of SRS-A however, at concentrations only slightly higher than those needed to inhibit SRS-A, FPL-55712 also inhibits thromboxane synthetase and lipoxygenase in broken cell, but not intact cell preparations. FPL-55712 also inhibits the extensive necrosis of liver parenchymal cells and death in animals injected with endotoxin and D-galactosamine. ... 

Orotic acid prevents experimental hepatitis induced by D-galactosamine. The experimental hepatitis paralleled by the accumulation of UDP derivatives of D-galactosamine was studied by Decker and co-workers [382-384]. On the basis of ultrastructural and biochemical analyses it was concluded that the liver damage observed after D-galactosamine treatment differs from that seen in human hepatitis in that the former leads to accumulation of liver triglycerides, hyperplasia of the smooth endoplasmic reticulum, and cell necrosis [385,386]. 

---